The Quantellect read.As of Nov 19, 2026, 10 active firms cover AnaptysBio Inc: 9 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $50.00 to $95.00, a moderate spread. The average target of $76.00 sits 61% above the current $47.12. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees revenue growth near -62% this year and 92% next, consensus EPS building from about $1.11 next quarter toward $4.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy990%
Neutral110%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$76.00
+61.3% upside
Average target across 10 active firms as of Nov 19, 2026 vs $47.12 current
Highest Target$95.00
Average Target$76.00
Lowest Target$50.00
Detailed analyst forecasts for ANAB
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 9 of 10 active firms rate ANAB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ANAB EPS & revenue forecast
EPS · NEXT QUARTER
$1.11
Range $1.11 – $1.11 · 1 analysts
Next period, 1 analysts expect AnaptysBio Inc to earn $1.11 a share (range $1.11 – $1.11), versus — a year earlier. Full-year consensus is $3.24, growing to $4.63 the year after.
REVENUE · NEXT QUARTER
$41.2M
Range $41.2M – $41.2M · 1 analysts · -30% YoY
Revenue is expected to reach $41.2M (range $41.2M – $41.2M), -30.0% year-over-year. Full-year consensus is $136.7M, rising to $164.5M next year.
Top analysts covering AnaptysBio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ANAB.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$75.00+59.2% to target
Overall win rate
48%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #84
Buy
$140.00+197.1% to target
Overall win rate
50%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Buy
$60.00+27.3% to target
Overall win rate
48%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$93.00+97.4% to target
Overall win rate
30%
+ Follow
#5
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$95.00+101.6% to target
Overall win rate
34%
+ Follow
ANAB stock forecast FAQ
What is ANAB's average 12-month price target?+
The 10 active firms with a live target average $76.00 for AnaptysBio Inc over the next 12 months, ranging from a $95.00 high to a $50.00 low, as of Nov 19, 2026.
Is ANAB stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ANAB?+
The Street-high target is $95.00 (HC Wainwright & Co.), and the Street-low is $50.00 (Truist Securities). The average of all 10 active-firm targets is $76.00.
How many active Wall Street firms cover ANAB?+
10 active firms have a recognized rating on AnaptysBio Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ANAB?+
Among analysts who currently cover ANAB, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $75.00 target.
What is AnaptysBio Inc's projected EPS for next quarter?+
The consensus estimate is $1.11 per share (range $1.11 – $1.11) across 1 analysts. Full-year EPS is projected at $3.24, rising to $4.63 the following year.
How much revenue is AnaptysBio Inc expected to report next quarter?+
Consensus revenue is $41.2M (range $41.2M – $41.2M). Full-year revenue is projected at $136.7M, growing to $164.5M next year.
Have analysts been upgrading or downgrading ANAB lately?+
As of Nov 19, 2026, 9 of 10 active firms rate ANAB a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ANAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.